1. Home
  2. ITOC vs APVO Comparison

ITOC vs APVO Comparison

Compare ITOC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITOC

iTonic Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$0.28

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

N/A

Current Price

$1.79

Market Cap

4.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ITOC
APVO
Founded
1998
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.3M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
ITOC
APVO
Price
$0.28
$1.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 745.8K
114.1K
Earning Date
03-20-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.13
EPS
★ N/A
N/A
Revenue
N/A
★ $3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.50
52 Week High
$1.15
$10.70

Technical Indicators

Market Signals
Indicator
ITOC
APVO
Relative Strength Index (RSI) 43.83 N/A
Support Level $0.27 N/A
Resistance Level $0.36 N/A
Average True Range (ATR) 0.04 0.00
MACD -0.00 0.00
Stochastic Oscillator 8.76 0.00

Price Performance

Historical Comparison
ITOC
APVO

About ITOC iTonic Holdings Ltd Class A Ordinary Shares

iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: